​

RenovoRx Stock (NASDAQ:RNXT)

ForecastRevenueOwnershipFinancialsChartTranscripts
RenovoRx by TradingView

Previous Close

$0.85

52W Range

$0.70 - $1.45

50D Avg

$0.91

200D Avg

$0.99

Market Cap

$32.18M

Avg Vol (3M)

$377.30K

Beta

1.00

Div Yield

-

RNXT Company Profile

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Aug 26, 2021

Website

RNXT Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24
Other Operating Segment$1.12M$43.00K

Fiscal year ends in Dec 24 | Currency in USD

RNXT Financial Summary

Dec 24Dec 23Dec 22
Revenue$43.00K--
Operating Income$-10.97M$-11.40M$-9.95M
Net Income$-8.81M$-10.23M$-9.77M
EBITDA$-10.97M$-11.39M$-9.94M
Basic EPS$-0.04$-0.99$-1.08
Diluted EPS$-0.04$-0.99$-1.08

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 26May 14, 26 | 4:30 PM
Q3 25Nov 13, 25 | 4:30 PM
Q2 25Aug 14, 25 | 4:30 PM

Peer Comparison

TickerCompany
TVRDTvardi Therapeutics, Inc.
ANVSAnnovis Bio, Inc.
CELUCelularity Inc.
ELUTElutia Inc.
CALCCalciMedica, Inc.
BCABBioAtla, Inc.
RVPHReviva Pharmaceuticals Holdings, Inc.
LTRNLantern Pharma Inc.
PYPDPolyPid Ltd.